HCWB$1.11-0.89%
HCW Biologics Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$2.48M
Float & O/S:
Inst Own:
DilutionScan read 31 of HCW Biologics Inc.'s SEC filings and found 12 warrant series, 2 convertibles, 1 ATM program, 1 equity line, 1 shelf registration, 8 S-1 registrations and 5 completed offerings on file for HCWB. The latest dilution event on file is a registration statement on Oct 9, 2026. Analysis updated Oct 14, 2026.
Signal8 Summary
HCWB
Going-concern warning, severe cash strain
Snapshot
HCWB is a preclinical/clinical-stage biotech with almost no revenue ($54K in FY 2025) and a net loss of $8.0M. It had just $741K in cash as of June 30, 2026 against $6.6M of debt, and auditors flagged going-concern doubt.
What's Happening Right Now
- : HCW Biologics filed an S-1 to register resale of 1.24M shares tied to its July 2026 PIPE, roughly 67% of shares outstanding, creating a severe dilution overhang.
- : HCW Biologics signed an exclusive worldwide (ex-China) distribution deal with Akron Biotech on Sept 4, 2026 to commercialize its HCW11-006 reagent, its first product to reach commercialization, with modest upfront payments.
- : HCW Biologics' Q2 2026 10-Q carries explicit going-concern language, with just $741K in cash against $18.6M of current liabilities and $107.5M in cumulative losses since inception.
- : HCW Biologics restated its Q1 2026 EPS down to $1.39 from $2.19 after misapplying an accounting method, and disclosed an unremediated internal-controls weakness alongside the going-concern doubt.
- : Registered additional securities for sale on Form S-1.
- : Registered 1.24M shares for sale on Form S-1.
- : Raised $1.60M in gross proceeds through a private placement (PIPE), with warrants over 400K shares.
- : HCW Biologics completed a 1-for-6 reverse stock split effective June 30, 2026, its second reverse split in about 15 months, to stay compliant with Nasdaq's minimum bid price rule.
